Actavis (ACT) PT Lifted to $340 at Argus
Tweet
Share
E-mailGet Alerts ACT Hot Sheet
Price: $42.72 --0%
Rating Summary:
14 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 10 | New: 13
Rating Summary:
14 Buy, 6 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 10 | New: 13
Join SI Premium – FREE
Argus reiterated a Buy rating and boosted its price target on Actavis (NYSE: ACT) to $340.00 (from $310.00), noting the company is gnerating strong growth, while also preparing for the Allergan acquisition.
The firm is boosting 2015 stand-alone adj-EPS from $16.55 to $16.80, indicating 20% growth. The stock looks attractive a current levels, the analyst said.
For an analyst ratings summary and ratings history on Actavis click here. For more ratings news on Actavis click here.
Shares of Actavis closed at $289.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Evercore ISI Downgrades Inspire Medical Systems (INSP) to In Line
- Wolfe Research Upgrades Target (TGT) to Outperform
- Evercore ISI Starts Permian Resources Corp (PR) at Outperform
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst PT ChangeRelated Entities
Argus, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
